Robert K McClure
Affiliation: University of North Carolina
- Regional change in brain morphometry in schizophrenia associated with antipsychotic treatmentRobert K McClure
University of North Carolina at Chapel Hill, Department of Psychiatry, Chapel Hill, NC 27510 7160, USA
Psychiatry Res 148:121-32. 2006..Longitudinal regional brain volume change in schizophrenia patients is likely physiologic and therefore potentially reversible...
- Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatmentRobert K McClure
University of North Carolina at Chapel Hill, Department of Psychiatry, Chapel Hill, North Carolina 27510 7160, United States
Schizophr Res 98:29-39. 2008..Although the results do not directly show that brief periods of atypical antipsychotic treatment are associated with basal ganglia and cortical volume change, there is much evidence to suggest that such an association exists...
- Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic typeRobert K McClure
Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
Psychiatry Res 211:1-10. 2013..Treatment-related related longitudinal shape change was not observed within the studied timeframe. Our results provide additional evidence for disrupted cortico-basal ganglia-thalamo-cortical circuits in schizophrenia...
- Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factorsMartin Styner
Department of Computer Science, University of North Carolina, Chapel Hill, NC 27599 3175, USA
Proc Natl Acad Sci U S A 102:4872-7. 2005..Our results suggest that genetics have a stronger influence on the shape of lateral ventricles than do the disease-related changes in schizophrenia...
- Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?Daniel R Weinberger
Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Dr, Bldg 10, Room 3C 101, MSC 1255, Bethesda, MD 20892, USA
Arch Gen Psychiatry 59:553-8. 2002
- Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case seriesStefano Marenco
Intramural Research Program, Clinical Brain Disorders Branch, National Institute of Mental Health, Building 10, Room 4S235, Bethesda, MD 20892, USA
Schizophr Res 57:221-6. 2002..No clear improvement in psychosis or in cognition was observed over the course of the study. CX516 at the doses tested did not appear to yield dramatic effects as a sole agent, but inference from this study is limited...